tiprankstipranks

Biogen reports Q1 EPS $3.40, consensus $3.28

Reports Q1 revenue $2.46B, consensus $2.34B. President and CEO Christopher Viehbacher said: "In the first quarter, we continued to make strong progress against our business priorities, most importantly execution of three potential launches in 2023. Biogen is at the forefront of groundbreaking science as demonstrated by our ability to help advance new surrogate biomarkers in Alzheimer’s disease and ALS while also delivering breakthrough data to address tau pathology in Alzheimer’s. I believe these achievements represent Biogen at its best. We also continue to remain diligent in prioritizing our R&D pipeline, optimizing our operating model, and evaluating external opportunities as we work to establish a sustainable growth trajectory."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on BIIB:

Disclaimer & DisclosureReport an Issue